Inactive Instrument

Constellation Pharmaceuticals, Inc.

Equities

CNST

US2103731061

Biotechnology & Medical Research

Constellation Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 10, 2021 at 06:06 am EDT

Constellation Pharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 40.226 million compared to USD 25.983 million a year ago. Net loss was USD 40.072 million compared to USD 25.444 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 0.61 a year ago.

Latest news about Constellation Pharmaceuticals, Inc.

MorphoSys Out Licenses Pre-Clinical Oncology Program	22-12-06	CI
MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	21-07-16	MT
Sector Update: Health Care Stocks Lower Just Ahead of Closing Bell	21-07-15	MT
Sector Update: Health Care Stocks Lacking Much Traction	21-07-15	MT
Constellation Announces Management Changes	21-07-15	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	21-07-15	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	21-07-15	CI
DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	21-07-15	MT
Sector Update: Health Care Stocks Flat To Lower Pre-Bell Thursday	21-07-15	MT
MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	21-07-15	MT
MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	21-07-15	MT
Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	21-07-15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	21-07-15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	21-07-15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	21-07-15	CI
MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	21-07-14	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from NASDAQ Biotechnology Index	21-07-14	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2000 Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2000 Value Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell Small Cap Comp Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2500 Value Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 3000 Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000 Value Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2500 Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000E Value Index	21-06-25	CI

Chart Constellation Pharmaceuticals, Inc.

Duration

Period

Chart Constellation Pharmaceuticals, Inc.

More charts

Company Profile

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-2.85%	21.93B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-5.29%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-10.09%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.45B

Bio Therapeutic Drugs